top of page

Research Watch

Pancreatic cancer 13 August 18

Mahajan UM, Langhoff E, Goni E, Costello E, Greenhalf W, Halloran C, Ormanns S, Kruger S, Boeck S, Ribback S, Beyer G, Dombroswki F, Weiss F-U, Neoptolemos JP, Werner J, D’Haese JG, Bazhin A, Peterhansl J, Pichlmeier S, Büchler MW, Kleeff J, Ganeh P, Sendler M, Palmer DH, Kohlmann T, Rad R, Regel I, Lerch MM, Mayerle J

 

Immune Cell and Stromal Signature Associated with Progression-free Survival of Patients with Resected Pancreatic Ductal Adenocarcinoma, Gastroenterology (2018), doi: 10.1053/j.gastro.2018.08.009.

In PDAC, the density of inflammatory infiltrate and stroma have been associated with survival.  In this study, the authors investigated the landscape of inflammatory infiltrates and stromal composition using immunohistochemistry, and correlated these with survival data in 385 patients from a randomised controlled adjuvant trial (5-FU/folinic acid vs gemcitabine).  

​

There was no difference in survival between the two treatment arms.  Inflammatory cell and stromal composition within the PDACs were assessed using immunohistochemistry for CD3, CD4, CD8, CD68, CD206 and chloracetate esterase, SMA and type 1 collagen.  Stromal composition was not associated with survival.  High density of CD3, CD4, CD8, CD68 and CD206 were all associated with better survival, and high level of CD3+ was the strongest independent marker of longer progression-free survival.

 

   

​

​

​

​

Read more..

bottom of page